Treatment for Multiple Myeloma

About

This patent-pending technology is a SR-18465 compound, which is an osteoclastogenesis matrix metalloproteinase 13 (MMP-13) highly specific inhibitor for the treatment of multiple myeloma. The compound specifically inhibits MMP-13 rather than the entire MMP family of endogenous proteins. SR-18465 directly impacts the viability of several multiple myeloma cell lines by up to 50% over 48 hours but had minimal effects on stromal cells of the bone microenvironment. Most significantly, in vivo SR-18465 significantly reduces the growth of multiple myeloma and, subsequently tumor burden.